Journal of Drug Targeting最新文献_第9页

Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing. 克服抗生素耐药性：药物再利用的潜力与陷阱。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-12 DOI: 10.1080/1061186X.2024.2424895

Mohammad Abavisani, Alireza Khoshrou, Souzan Eshaghian, Sercan Karav, Amirhossein Sahebkar

{"title":"Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing.","authors":"Mohammad Abavisani, Alireza Khoshrou, Souzan Eshaghian, Sercan Karav, Amirhossein Sahebkar","doi":"10.1080/1061186X.2024.2424895","DOIUrl":"10.1080/1061186X.2024.2424895","url":null,"abstract":"Since its emergence shortly after the discovery of penicillin, antibiotic resistance has escalated dramatically, posing a significant health threat and economic burden. Drug repositioning, or drug repurposing, involves identifying new therapeutic applications for existing drugs, utilising their established safety profiles and pharmacological data to swiftly provide effective treatments against resistant pathogens. Several drugs, including otilonium bromide, penfluridol, eltrombopag, ibuprofen, and ceritinib, have demonstrated potent antibacterial activity against multidrug-resistant (MDR) bacteria. These drugs can disrupt biofilms, damage bacterial membranes, and inhibit bacterial growth. The combination of repurposed drugs with conventional antibiotics can reduce the required dosage of individual drugs, mitigate side effects, and delay the development of resistance, making it a promising strategy against MDR bacteria such as Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. Despite its promise, drug repurposing faces challenges such as potential off-target effects, toxicity, and regulatory and intellectual property issues, necessitating rigorous evaluations and strategic solutions. This article aims to explore the potential of drug repurposing as a strategy to combat antibiotic resistance, examining its benefits, challenges, and future prospects. We address the legal, economic, and practical challenges associated with repurposing existing drugs, highlight successful examples, and propose solutions to enhance the efficacy and viability of this approach in combating MDR bacterial infections.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-27"},"PeriodicalIF":4.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive developmental investigation on simvastatin enriched bioactive film forming spray using the quality by design paradigm: a prospective strategy for improved wound healing. 利用设计质量范式对辛伐他汀富含生物活性成膜喷雾剂进行综合开发研究：改善伤口愈合的前瞻性策略。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-07-29 DOI: 10.1080/1061186X.2024.2382405

Vrushali N Patel, Heta V Patel, Kashish Agrawal, Ishika Soni, Pranav Shah, Shubhada V Mangrulkar, Milind J Umekar, Manisha S Lalan

{"title":"Comprehensive developmental investigation on simvastatin enriched bioactive film forming spray using the quality by design paradigm: a prospective strategy for improved wound healing.","authors":"Vrushali N Patel, Heta V Patel, Kashish Agrawal, Ishika Soni, Pranav Shah, Shubhada V Mangrulkar, Milind J Umekar, Manisha S Lalan","doi":"10.1080/1061186X.2024.2382405","DOIUrl":"10.1080/1061186X.2024.2382405","url":null,"abstract":"The use of topical antimicrobials in wound healing presents challenges like risk of drug resistance and toxicity to local tissue. Simvastatin (SIM), a lipid-lowering agent which reduces the risk of cardiovascular events, is repurposed for its pleiotropic effect in wound healing. A bioactive bioadhesive polymer-based film forming spray (FFS) formulation of SIM was designed using chitosan, collagen, hyaluronic acid and optimised by employing the DoE approach. Optimised formulation demonstrated moderate viscosity (12.5 ± 0.3 cP), rapid film formation (231 ± 5.6 s), flexibility, tensile strength and sustained drug release (T80 - time for 80% drug release - 9.05 ± 0.7 h). Scanning electron microscopy (SEM) verified uniformly dispersed drug within the composite polymer matrix. SIM FFS demonstrated antimicrobial activity against gram positive and gram negative bacteria. In vivo excision wound model studies in mice affirmed the beneficent role of bioactive polymers and the efficacy of SIM FFS in wound contraction and closure, tissue remodelling and re-epithelization in comparison to standard antimicrobial preparation. Cytokines TNF- alpha, IL-6 were downregulated and IL-10 was upregulated. Biochemical markers; hydroxyproline, hexosamine and histopathology were consistent with wound contraction observed. This is an exploratory effort in repurposing SIM for wound healing in a novel dosage form, underscoring its potential as an alternative to conventional topical antimicrobials.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1139-1153"},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Edoxaban enfolded beta-1,4-poly-d-glucosamine nanoparticles for targeting eponym Stuart-Prower factor for treatment of venous thrombosis. 埃多沙班包覆 beta-1,4-聚-D-葡糖胺纳米颗粒，用于靶向治疗静脉血栓的匿名斯图尔特-普罗因子。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-07-22 DOI: 10.1080/1061186X.2024.2377611

Pavazhaviji Pazhani, Jose Prakash Dharmian, Somasundaram Arumugam, Pavithra Pazhani, Vijaya Vara Prasad Medapati

{"title":"Edoxaban enfolded beta-1,4-poly-d-glucosamine nanoparticles for targeting eponym Stuart-Prower factor for treatment of venous thrombosis.","authors":"Pavazhaviji Pazhani, Jose Prakash Dharmian, Somasundaram Arumugam, Pavithra Pazhani, Vijaya Vara Prasad Medapati","doi":"10.1080/1061186X.2024.2377611","DOIUrl":"10.1080/1061186X.2024.2377611","url":null,"abstract":"The present research looked for ways to develop shielded nanoparticles (NPs)-drug transporters made of chitosan (CS) to enhance the bioavailability of edoxaban tosylate monohydrate (ETM) for oral administration by examining the correlation among design aspects and data from experiments using response surface methodology (RSM). ETM-loaded CS nanoparticles (ETM-CS-NPs) were developed using the ionic gelation of CS with tripolyphosphate (TPP). Utilising Zeta-sizer and scanning electron microscopy, the ETM-CS-NPs were evaluated for particle size (PS), zeta potential (ZP), surface morphology, polydispersity index (PDI), entrapment efficiency (EE) and drug loading (DL). Drug and polymer interactions in NPs were assessed using Fourier transform infra-red spectroscopy. The response surface approach and Design-Expert software optimised the ETM-CS-NPs. Using RSM, the effects of independent variables such as the amount of CS, the amount of TPP, and the amount of glacial acetic acid on PS, PDI and ZP were analysed. The optimal combination of PS (354.8 nm), PDI (0.509), ZP (43.7 + mV), % EE (70.3 ± 1.3) and % DL (9.1 ± 0.4) has been identified for the optimised ETM-CS-NPs. ETM-CS-NPs' anticoagulant activity was evaluated using activated partial thromboplastin time (aPTT), prothrombin time (PT) and thrombin time (TT) assays. In conclusion, a practical and consistent method has been established, and its application has been proven in vitro, indicating its utility for future studies of the biological distribution of ETM-CS-NPs in vivo for specific antithrombotic treatments.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1125-1138"},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

S-(N,N-diethyldithiocarbamoyl)-N-acetyl-l-cysteine for the treatment of non-small cell lung cancer through regulating NF-κB signalling pathway without neurotoxicity. S-(N,N-二乙基二硫代氨基甲酰基)-N-乙酰-L-半胱氨酸通过调节 NF-κB 信号通路治疗非小细胞肺癌而不产生神经毒性

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-07-12 DOI: 10.1080/1061186X.2024.2374037

Huaiyou Lv, Huatian Yang, Yifei Duan, Chongzheng Yan, Genju Li, Guozhi Zhao, Fengqin Sun, Yafei Feng, Yuhan Li, Yaqing Fu, Yizhe Li, Zhongxi Zhao, Xiumei Jia

{"title":"S-(N,N-diethyldithiocarbamoyl)-N-acetyl-l-cysteine for the treatment of non-small cell lung cancer through regulating NF-κB signalling pathway without neurotoxicity.","authors":"Huaiyou Lv, Huatian Yang, Yifei Duan, Chongzheng Yan, Genju Li, Guozhi Zhao, Fengqin Sun, Yafei Feng, Yuhan Li, Yaqing Fu, Yizhe Li, Zhongxi Zhao, Xiumei Jia","doi":"10.1080/1061186X.2024.2374037","DOIUrl":"10.1080/1061186X.2024.2374037","url":null,"abstract":"The discovery of novel targeted agents for non-small cell lung cancer (NSCLC) remains an important research landscape due to the limited efficacy, side effects and drug resistance of current treatment options. Among many repurposed drugs, disulphiram (DSF) has shown the potential to target tumours. However, its unpleasant neurotoxicity greatly limits its use. A DSF derivative, S-(N,N-diethyldithiocarbamoyl)-N-acetyl-l-cysteine (DS-NAC), was synthesised against NSCLC. The therapeutic effects, mechanism and toxicities of DS-NAC were evaluated in A549 and H460 cells and the mouse model of in situ lung cancer. The in vitro results exhibited that DS-NAC had potent anti-proliferation, apoptotic, anti-metastasis and epithelial-mesenchymal transition (EMT) inhibition effects. In the orthotopic lung cancer mouse model, therapeutic effects of DS-NAC were better than those of DSF and were similar to docetaxel (DTX). Also, results from western blot and immunohistochemistry showed that DS-NAC in combination with copper exerted therapeutic effects via regulating NF-κB signalling pathway and ROS-related proteins such as HIF-1α, Nrf2 and PKC-δ rather than regulating ROS level directly. Moreover, the safety evaluation study showed that DS-NAC had low haematologic and hepatic toxicities in comparison with DTX as well as low neurological toxicity compared with DSF. DS-NAC could be a promising anti-lung cancer agent with a favourable safety profile.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1111-1124"},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Green synthesis of gold nanoparticles in an animal model of chronic wound induced with Resiquimod. 在瑞舒莫德诱导的慢性伤口动物模型中绿色合成金纳米粒子。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-07-12 DOI: 10.1080/1061186X.2024.2373304

Carolini Mendes, Rubya Pereira Zaccaron, Laura de Roch Casagrande, Ligia Milanez Venturini, Camila da Costa, Igor Ramos Lima, Tiago Bender Wermuth, Sabrina Arcaro, Paulo Emilio Feuser, Paulo Cesar Lock Silveira

{"title":"Green synthesis of gold nanoparticles in an animal model of chronic wound induced with Resiquimod.","authors":"Carolini Mendes, Rubya Pereira Zaccaron, Laura de Roch Casagrande, Ligia Milanez Venturini, Camila da Costa, Igor Ramos Lima, Tiago Bender Wermuth, Sabrina Arcaro, Paulo Emilio Feuser, Paulo Cesar Lock Silveira","doi":"10.1080/1061186X.2024.2373304","DOIUrl":"10.1080/1061186X.2024.2373304","url":null,"abstract":"Cost-effective strategies for the treatment of chronic wounds must be developed. The green synthesis of gold nanoparticles (GNPs) it is possible to guarantee a lower toxicity in biological tissues and greater safety of applicability, in addition to adding the effects of nanoparticles (NPs) to those of extracts. The objective of this study was to evaluate the effects of treatment with biosynthesized GNPs in a chronic wound model. Wistar rats were distributed into 7 groups: Acute Wound (AW); Chronic wound (CW); CW + GNPs-Açaí; CW + GNPs-DB; CW + AV-GNPs; CW + SafGel®; CW + 660 nm laser. The chronic injury model was induced with topically applied Resiquimod for 6 days. Treatments were then initated on the fourteenth day after the last application of Resiquimod and carried out daily for ten days. The proposed therapies with GNPs were able to significantly reduce the inflammatory score and increase the rate of wound contraction. In histology, there was a reduction in the inflammatory infiltrate and increased gene expression of fibronectin and type III collagen, mainly in the CW + AV-GNPs group. The therapies were able to reduce pro-inflammatory cytokines, increase anti-inflammatory cytokines, and reduce oxidative stress. The results demonstrated that the effects of GNPs appear to complement those of the extracts, thereby enhancing the tissue repair process.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1086-1100"},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nano-based drug delivery systems in hepatocellular carcinoma. 肝细胞癌中的纳米给药系统

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-06-18 DOI: 10.1080/1061186X.2024.2365937

Maryam Sadat Abtahi, Alireza Fotouhi, Niloufar Rezaei, Hilal Akalin, Yusuf Ozkul, Nikoo Hossein-Khannazer, Massoud Vosough

引用次数: 0

An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles. 克服耐药性的一体化纳米颗粒：多柔比星和 Elacridar 共载叶酸受体靶向 PLGA/MSN 混合纳米颗粒。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1080/1061186X.2024.2374034

Hayrettin Tonbul, Adem Şahin, Süleyman Can Öztürk, Gözde Ultav, Ece Tavukçuoğlu, Sedenay Akbaş, Yeşim Aktaş, Güneş Esendağlı, Yılmaz Çapan

{"title":"An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles.","authors":"Hayrettin Tonbul, Adem Şahin, Süleyman Can Öztürk, Gözde Ultav, Ece Tavukçuoğlu, Sedenay Akbaş, Yeşim Aktaş, Güneş Esendağlı, Yılmaz Çapan","doi":"10.1080/1061186X.2024.2374034","DOIUrl":"10.1080/1061186X.2024.2374034","url":null,"abstract":"Overexpression of permeability-glycoprotein (P-gp) transporter leads to multidrug resistance (MDR) through cellular exclusion of chemotherapeutics. Co-administration of P-gp inhibitors and chemotherapeutics is a promising approach for improving the efficacy of therapy. Nevertheless, problems in pharmacokinetics, toxicity and solubility limit the application of P-gp inhibitors. Herein, we developed a novel all-in-one hybrid nanoparticle system to overcome MDR in doxorubicin (DOX)-resistant breast cancer. First, folic acid-modified DOX-loaded mesoporous silica nanoparticles (MSNs) were prepared and then loaded into PEGylated poly(lactic-co-glycolic acid) (PLGA) nanoparticles along with a P-gp inhibitor, elacridar. This hybrid nanoparticle system had high drug loading capacity, enabled both passive and active targeting of tumour tissues, and exhibited sequential and pH-triggered release of drugs. In vitro and in vivo studies in DOX-resistant breast cancer demonstrated the ability of the hybrid nanoparticles to reverse P-gp-mediated drug resistance. The nanoparticles were efficiently taken up by the breast cancer cells and delivered elacridar, in vitro. Biodistribution studies demonstrated substantial accumulation of the folate receptor-targeted PLGA/MSN hybrid nanoparticles in tumour-bearing mice. Moreover, deceleration of the tumour growth was remarkable in the animals administered with the DOX and elacridar co-loaded hybrid nanoparticles when compared to those treated with the marketed liposomal DOX (Caelyx®) or its combination with elacridar.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1101-1110"},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141468479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting anticancer immunity in melanoma tumour microenvironment: unleashing the potential of adjuvants, drugs, and phytochemicals. 瞄准黑色素瘤肿瘤微环境中的抗癌免疫：释放佐剂、药物和植物化学物质的潜力。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-08-07 DOI: 10.1080/1061186X.2024.2384071

Jingping Wang, Yaping Wang, Xiaofang Jiang

{"title":"Targeting anticancer immunity in melanoma tumour microenvironment: unleashing the potential of adjuvants, drugs, and phytochemicals.","authors":"Jingping Wang, Yaping Wang, Xiaofang Jiang","doi":"10.1080/1061186X.2024.2384071","DOIUrl":"10.1080/1061186X.2024.2384071","url":null,"abstract":"Melanoma poses a challenge in oncology because of its aggressive nature and limited treatment modalities. The tumour microenvironment (TME) in melanoma contains unique properties such as an immunosuppressive and high-density environment, unusual vasculature, and a high number of stromal and immunosuppressive cells. In recent years, numerous experiments have focused on boosting the immune system to effectively remove malignant cells. Adjuvants, consisting of phytochemicals, toll-like receptor (TLR) agonists, and cytokines, have shown encouraging results in triggering antitumor immunity and augmenting the therapeutic effectiveness of anticancer therapy. These adjuvants can stimulate the maturation of dendritic cells (DCs) and infiltration of cytotoxic CD8+ T lymphocytes (CTLs). Furthermore, nanocarriers can help to deliver immunomodulators and antigens directly to the tumour stroma, thereby improving their efficacy against malignant cells. The remodelling of melanoma TME utilising phytochemicals, agonists, and other adjuvants can be combined with current modalities for improving therapy outcomes. This review article explores the potential of adjuvants, drugs, and their nanoformulations in enhancing the anticancer potency of macrophages, CTLs, and natural killer (NK) cells. Additionally, the capacity of these agents to repress the function of immunosuppressive components of melanoma TME, such as immunosuppressive subsets of macrophages, stromal and myeloid cells will be discussed.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1052-1072"},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of crotonylation modification in pan-vascular diseases. 巴豆酰化修饰在泛血管疾病中的应用

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-07-04 DOI: 10.1080/1061186X.2024.2372316

Wendi Yan, Yang Zhang, Yuxiang Dai, Junbo Ge

{"title":"Application of crotonylation modification in pan-vascular diseases.","authors":"Wendi Yan, Yang Zhang, Yuxiang Dai, Junbo Ge","doi":"10.1080/1061186X.2024.2372316","DOIUrl":"10.1080/1061186X.2024.2372316","url":null,"abstract":"Pan-vascular diseases, based on systems biology theory, explore the commonalities and individualities of important target organs such as cardiovascular, cerebrovascular and peripheral blood vessels, starting from the systemic and holistic aspects of vascular diseases. The purpose is to understand the interrelationships and results between them, achieve vascular health or sub-health, and comprehensively improve the physical and mental health of the entire population. Post-translational modification (PTM) is an important part of epigenetics, including phosphorylation, acetylation, ubiquitination, methylation, etc., playing a crucial role in the pan-vascular system. Crotonylation is a novel type of PTM that has made significant progress in the research of pan-vascular related diseases in recent years. Based on the review of previous studies, this article summarises the various regulatory factors of crotonylation, physiological functions and the mechanisms of histone and non-histone crotonylation in regulating pan-vascular related diseases to explore the possibility of precise regulation of crotonylation sites as potential targets for disease treatment and the value of clinical translation.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"996-1004"},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aptamers: ushering in new hopes in targeted glioblastoma therapy. aptamers：为胶质母细胞瘤靶向治疗带来新希望。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-11-01 Epub Date: 2024-07-03 DOI: 10.1080/1061186X.2024.2373306

Debarpan Chatterjee, Srijan Bhattacharya, Leena Kumari, Aparna Datta

引用次数: 0